Cargando…

Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach

Cancer is one of the most complex diseases that has resulted in multiple genetic disorders and cellular abnormalities. Globally, cancer is the most common health concern disease that is affecting human beings. Great efforts have been made over the past decades in biology with the aim of searching no...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmoodi Chalbatani, Ghanbar, Dana, Hassan, Gharagouzloo, Elahe, Grijalvo, Santiago, Eritja, Ramon, Logsdon, Craig D, Memari, Fereidoon, Miri, Seyed Rouhollah, Rad, Mahdi Rezvani, Marmari, Vahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504672/
https://www.ncbi.nlm.nih.gov/pubmed/31118626
http://dx.doi.org/10.2147/IJN.S200253
_version_ 1783416608691060736
author Mahmoodi Chalbatani, Ghanbar
Dana, Hassan
Gharagouzloo, Elahe
Grijalvo, Santiago
Eritja, Ramon
Logsdon, Craig D
Memari, Fereidoon
Miri, Seyed Rouhollah
Rad, Mahdi Rezvani
Marmari, Vahid
author_facet Mahmoodi Chalbatani, Ghanbar
Dana, Hassan
Gharagouzloo, Elahe
Grijalvo, Santiago
Eritja, Ramon
Logsdon, Craig D
Memari, Fereidoon
Miri, Seyed Rouhollah
Rad, Mahdi Rezvani
Marmari, Vahid
author_sort Mahmoodi Chalbatani, Ghanbar
collection PubMed
description Cancer is one of the most complex diseases that has resulted in multiple genetic disorders and cellular abnormalities. Globally, cancer is the most common health concern disease that is affecting human beings. Great efforts have been made over the past decades in biology with the aim of searching novel and more efficient tools in therapy. Thus, small interfering RNAs (siRNAs) have been considered one of the most noteworthy developments which are able to regulate gene expression following a process known as RNA interference (RNAi). RNAi is a post-transcriptional mechanism that involves the inhibition of gene expression through promoting cleavage on a specific area of a target messenger RNA (mRNA). This technology has shown promising therapeutic results for a good number of diseases, especially in cancer. However, siRNA therapeutics have to face important drawbacks in therapy including stability and successful siRNA delivery in vivo. In this regard, the development of effective siRNA delivery systems has helped addressing these issues by opening novel therapeutic windows which have allowed to build up important advances in Nanomedicine. In this review, we discuss the progress of siRNA therapy as well as its medical application via nanoparticle-mediated delivery for cancer treatment.
format Online
Article
Text
id pubmed-6504672
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65046722019-05-22 Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach Mahmoodi Chalbatani, Ghanbar Dana, Hassan Gharagouzloo, Elahe Grijalvo, Santiago Eritja, Ramon Logsdon, Craig D Memari, Fereidoon Miri, Seyed Rouhollah Rad, Mahdi Rezvani Marmari, Vahid Int J Nanomedicine Review Cancer is one of the most complex diseases that has resulted in multiple genetic disorders and cellular abnormalities. Globally, cancer is the most common health concern disease that is affecting human beings. Great efforts have been made over the past decades in biology with the aim of searching novel and more efficient tools in therapy. Thus, small interfering RNAs (siRNAs) have been considered one of the most noteworthy developments which are able to regulate gene expression following a process known as RNA interference (RNAi). RNAi is a post-transcriptional mechanism that involves the inhibition of gene expression through promoting cleavage on a specific area of a target messenger RNA (mRNA). This technology has shown promising therapeutic results for a good number of diseases, especially in cancer. However, siRNA therapeutics have to face important drawbacks in therapy including stability and successful siRNA delivery in vivo. In this regard, the development of effective siRNA delivery systems has helped addressing these issues by opening novel therapeutic windows which have allowed to build up important advances in Nanomedicine. In this review, we discuss the progress of siRNA therapy as well as its medical application via nanoparticle-mediated delivery for cancer treatment. Dove 2019-05-02 /pmc/articles/PMC6504672/ /pubmed/31118626 http://dx.doi.org/10.2147/IJN.S200253 Text en © 2019 Mahmoodi Chalbatani et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Mahmoodi Chalbatani, Ghanbar
Dana, Hassan
Gharagouzloo, Elahe
Grijalvo, Santiago
Eritja, Ramon
Logsdon, Craig D
Memari, Fereidoon
Miri, Seyed Rouhollah
Rad, Mahdi Rezvani
Marmari, Vahid
Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
title Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
title_full Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
title_fullStr Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
title_full_unstemmed Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
title_short Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
title_sort small interfering rnas (sirnas) in cancer therapy: a nano-based approach
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504672/
https://www.ncbi.nlm.nih.gov/pubmed/31118626
http://dx.doi.org/10.2147/IJN.S200253
work_keys_str_mv AT mahmoodichalbatanighanbar smallinterferingrnassirnasincancertherapyananobasedapproach
AT danahassan smallinterferingrnassirnasincancertherapyananobasedapproach
AT gharagouzlooelahe smallinterferingrnassirnasincancertherapyananobasedapproach
AT grijalvosantiago smallinterferingrnassirnasincancertherapyananobasedapproach
AT eritjaramon smallinterferingrnassirnasincancertherapyananobasedapproach
AT logsdoncraigd smallinterferingrnassirnasincancertherapyananobasedapproach
AT memarifereidoon smallinterferingrnassirnasincancertherapyananobasedapproach
AT miriseyedrouhollah smallinterferingrnassirnasincancertherapyananobasedapproach
AT radmahdirezvani smallinterferingrnassirnasincancertherapyananobasedapproach
AT marmarivahid smallinterferingrnassirnasincancertherapyananobasedapproach